Clinical Trial Update: A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating 20, 40, and 80 mg of sildenafil taken three times daily for pulmonary arterial hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Hypertension, Pulmonary | Phase 3 | Status: COMPLETED